---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-097919"
form_type: "8-K/A"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2025-10-08T23:59:59+00:00"
generated_at: "2026-05-17T04:20:30.368171+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# TransCode acquires ABCJ from CK Life Sciences unit; raises $25M in concurrent investment

## Summary
- Acquired 100% of ABCJ from DEFJ (CK Life Sciences sub) for 83,285 common and 1,152.9568 Series A Preferred shares.
- Concurrent investment: DEFJ buys 223.7337 Series B Preferred at $111,740/share, raising ~$25M ($20M cash + $5M promissory note at 4% due Jan 2026).
- Up to $95M in contingent milestone payments to DEFJ upon achievement of certain milestones.
- Each common shareholder receives one CVR, entitling holder to 50% of net proceeds from upfront/milestone payments over 7 years.
- Stockholder meeting needed to approve conversion of Series A Preferred and change of control under Nasdaq rules.

## SEC filing metadata
- accession: 0001104659-25-097919
- form_type: 8-K/A
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2025-10-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465925097919/0001104659-25-097919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465925097919/tm2528282d3_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-097919
- JSON: https://secwatch.observer/filing/0001104659-25-097919.json
- Plain text: https://secwatch.observer/filing/0001104659-25-097919.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.